Status:
COMPLETED
The Underlying Mechanisms For S. Aureus Infection And Colonization Of Skin in People With Atopic Dermatitis With And Without Eczema Herpeticum (MRSA)
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
Methicillin-Resistant Staphylococcus Aureus
Atopic Dermatitis
Eligibility:
All Genders
1-80 years
Brief Summary
Staphylococcus aureus (S.aureus) is a bacterium that causes many painful skin and soft tissue conditions, such as scalded-skin syndrome, boils, or impetigo. Serious cases may result in deadly complica...
Detailed Description
The emergence of drug-resistant staphylococcal strains was first seen in the US almost a decade ago, when the Centers for Disease Control (CDC) reported four fatal community-based MRSA infections in c...
Eligibility Criteria
Inclusion
- Parent, or legal guardian willing to provide informed consent, if necessary
- Residing in the U.S.
- Have active AD with or without a history of EH as diagnosed using the ADVN Standardized Diagnostic Criteria OR are non-atopic as diagnosed using the ADVN Standardized Diagnostic Criteria
Exclusion
- History of any systemic illness (i.e., immunodeficiency disorders such as human immunodeficiency virus \[HIV\] or lupus erythematosus) other than the condition being studied
- Presence of active systemic malignancy, excluding uncomplicated non-melanoma skin cancer
- Presence of any skin disease other than AD that might compromise the stratum corneum barrier (e.g., bullous disease, psoriasis, cutaneous T cell lymphoma \[also called Mycosis Fungoides or Sezary syndrome\])
- Use of topical medications including (but not limited to) Elidel, Protopic, or topical corticosteroids at the site of the skin lesion within the last 3 days
- Use of topical antibiotics within the last 24 hours
- Use of oral antibiotics within the last 10 days. Subjects who are known to be culture positive for MSSA or MRSA despite antibiotic treatment will not be excluded.
- History of serious or life-threatening reactions to tape or adhesives will be excluded from the tape stripping procedure
Key Trial Info
Start Date :
February 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2009
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT00822276
Start Date
February 1 2009
End Date
November 1 2009
Last Update
April 4 2014
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, San Diego
San Diego, California, United States, 92161
2
National Jewish Health
Denver, Colorado, United States, 80206